Stephen Yip
Overview
Explore the profile of Stephen Yip including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
187
Citations
4842
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsai C, Hennawy M, Yip S, Tosefsky K, Oh J, Fatehi M, et al.
Can J Neurol Sci
. 2025 Mar;
:1-8.
PMID: 40078155
No abstract available.
2.
Brandl B, Steiger M, Kubelt C, Rohrandt C, Zhu Z, Evers M, et al.
Nat Med
. 2025 Feb;
PMID: 40021833
Although the intraoperative molecular diagnosis of the approximately 100 known brain tumor entities described to date has been a goal of neuropathology for the past decade, achieving this within a...
3.
Yeo S, Sun J, Zibrik K, Shaipanich T, Carolan H, Melosky B, et al.
BMJ Open Qual
. 2025 Feb;
14(1).
PMID: 39971592
Background: Given how crucial molecular-biomarker testing is to treatment decisions for advanced non-small cell lung cancer (NSCLC), guidelines recommend a turnaround time (TAT) of 14 calendar days from receiving specimen...
4.
Tan S, Bettegowda C, Yip S, Sahgal A, Rhines L, Reynolds J, et al.
Global Spine J
. 2025 Jan;
15(1_suppl):16S-28S.
PMID: 39801114
Study Design: Narrative review. Objectives: This article aims to provide a narrative review of the current state of research for liquid biopsy in spinal tumors and to discuss the potential...
5.
Landry A, Wang J, Liu J, Patil V, Gui C, Patel Z, et al.
Neuro Oncol
. 2025 Jan;
PMID: 39775867
Background: Meningiomas exhibit considerable clinical and biological heterogeneity. We previously identified four distinct molecular groups (immunogenic, NF2-wildtype, hypermetabolic, proliferative) that address much of this heterogeneity. Despite the utility of these...
6.
Krishnan T, Solar Vasconcelos J, Titmuss E, Vanner R, Schaeffer D, Karsan A, et al.
Cancer Res Commun
. 2024 Dec;
5(1):66-73.
PMID: 39636207
Liquid biopsy is increasingly being used in oncology for tumor molecular characterization. CHIP is a common incidental finding in cfDNA, and its prevalence increases with age. This study builds on...
7.
Krebs E, Weymann D, Ho C, Bosdet I, Laskin J, Lim H, et al.
Lancet Reg Health Am
. 2024 Nov;
40:100936.
PMID: 39605959
Background: Multi-gene panel sequencing streamlines treatment selection for advanced non-small cell lung cancer (NSCLC). Implementation continues to be uneven across jurisdictions, partly due to uncertain clinical and economic impacts. In...
8.
ONeill K, Pleasance E, Fan J, Akbari V, Chang G, Dixon K, et al.
Cell Genom
. 2024 Oct;
4(11):100674.
PMID: 39406235
The Long-Read Personalized OncoGenomics (POG) dataset comprises a cohort of 189 patient tumors and 41 matched normal samples sequenced using the Oxford Nanopore Technologies PromethION platform. This dataset from the...
9.
Elder M, Yip S, Marzoughi S, Martin K, Fatehi Hassanabad M, Rizzuto M
Stroke
. 2024 Oct;
55(11):e316-e320.
PMID: 39381874
No abstract available.
10.
Koh L, Pang Q, Novera W, Lim S, Chong Y, Liu J, et al.
Neuro Oncol
. 2024 Oct;
27(2):398-414.
PMID: 39373211
Background: Enhancer of zeste homolog 2 (EZH2), well known for its canonical methyltransferase activity in transcriptional repression in many cancers including glioblastoma (GBM), has an understudied noncanonical function critical for...